Introduction: Patients with chronic obstructive pulmonary disease (COPD) have an increased risk of cardiovascular disease. The endothelial dysfunction likely plays a central role in increasing cardiovascular risk.
| IN TRO DUCT IO N
Chronic obstructive pulmonary disease (COPD) is a progressive disease of the lungs that is characterized by a persistent airflow limitation and is the third cause of morbidity and mortality worldwide. 1 Patients with COPD have an increased risk of cardiovascular disease, and cardiac complications are among the leading causes of death in COPD patients. 2 The mechanisms involved in the development of cardiovascular diseases in patients with a mainly lung disease are still being debate. Some factors involved in this relationship may be smoking, a shared risk factor between heart diseases and COPD and systemic inflammation associated with COPD. 2 Furthermore, it is known that airflow obstruction profoundly affects cardiac function and gas exchange, leading to systemic consequences. An increased prevalence of ischemic heart disease and hypertension is seen in COPD patients and these conditions are linked to poor prognosis. 3 Although the pathogenic mechanism that links COPD to vascular diseasesrelated is poorly understood, data have supported the potential contribution of vascular endothelial dysfunction and arterial stiffness. 4 Endothelial dysfunction is commonly described as the inability of the artery to sufficiently dilate in response to an appropriate endothelial stimulus. Endothelial homeostasis is involved in regulation of vasomotor tone, regulation of vascular smooth muscle cell proliferation and migration, thrombogenesis and fibrinolysis. 5 Previous studies have emphasized the importance of endothelial as a prognostic factor and an independent predictor of all-cause and cardiovascular mortality.
2 COPD patients also frequently exhibit endothelial dysfunction which can be the main cause of cardiac comorbidities. 6 The degree of endothelial dysfunction is proportional to disease severity measured by airway obstruction. 7, 8 Endothelial dysfunction can be assessed by different methods, the most widely utilized method is flow-mediated dilation (FMD) test, but is quite complex requiring the use of ultrasound, trained personal and is time consuming. Peripheral arterial tonometry (PAT) and pulse wave velocity (PWV) represent two noninvasive methods for assessing endothelial function at peripheral and central sites, respectively. PAT currently represents an easy, simple, noninvasive test to study endothelial function at the fingertip. 9 The major novelty of the present study is the application of this noninvasive and reproducible finger plethysmography PAT to detect endothelial dysfunction in COPD patients. The aim of the study was to assess the prevalence and the degree of endothelial dysfunction in a group of stable COPD patients compared with a group of healthy subjects and a group of subjects with treated arterial hypertension (AH). A secondary purpose was to determine the relationship between the degree of endothelial dysfunction and airflow limitation in patients with COPD.
| MAT ERI AL S A ND M ETH ODS

| Study design
This was a cross-sectional, observational, descriptive study. This study complied with the Declaration of Helsinki. It has approved by the local Review Board and each subject enrolled signed informed consent. The patients were enrolled between April and December 2015, at both the Unit of Internal Medicine and Cardiology of University and Hospital of Brescia. Enrolled subjects underwent a single visit where medical history and the subject's characteristics were collected. In the same visit respiratory function tests and PAT were recorded. 10 Criteria for exclusion were the presence of one of the following characteristics: history of any cardiovascular disease (except AH), diabetes mellitus, COPD exacerbation or respiratory infections in previous 6 months, diagnosis of asthma or other pulmonary diseases.
| Subjects
| Study measurements
Medical history, respiratory function tests, and PAT were recorded for each participant. Active smoking was defined if a current consumption of >2 cigarettes/day was reported; the number of pack/year was also recorded.
| Blood pressure, heart rate and comorbidities
Systemic AH was defined if assuming antihypertensive treatment, in the presence of a medical history with documented high blood pressure (BP), if systolic BP >140 mm Hg and/ or diastolic BP > 90 mm Hg on three separate occasions.
11
Systolic (SBP), diastolic blood (DBP) pressure and heart rate (HR) were measured in the lying position, at one-minute intervals, on three occasions according to ESH-ESC guidelines (2003). 11 The mean values of SBP, DBP and HR were reported. Coexisting chronic diseases were identified by examining the clinical documentation.
| Respiratory function tests
Lung spirometry was performed in accordance with the standard procedures. 12 Forced Vital Capacity (FVC) and Forced Expiratory Volume in the first second (FEV 1 ) were recorded with the subject sitting, and the spirometry maneuver was repeated at least three times. The best results were
The percent-of-predicted values were calculated from the European Respiratory Society's standards data. 13 
| Endothelial function
PAT signals were obtained using the EndoPAT-2000 device (Itamar Medical Ltd, Caesarea, Israel), which has been validated and used previously to assess peripheral arterial tone in other populations. [14] [15] [16] Specially designed finger probes are placed on the middle finger of each subject's hands. These probes comprised a system of inflatable latex air cuffs connected by pneumatic tubes to an inflating device controlled through a computer algorithm. A constant counter pressure (pre-determined by baseline diastolic blood pressure) is applied through the air cushions, this prevents venous pooling, thus avoiding venous-arteriolar reflex vasoconstriction, with no occlusion of arterial blood flow. Pulsate volume changes of the distal digit induce pressure alterations in the finger cuff, which are sensed by pressure transducers and transmitted to and recorded by the EndoPAT-2000 device. A decrease in the arterial blood volume in the distal fingertip causes a decrease in pulsatile arterial column changes, reflected as a decrease in the measured PAT signal, and vice versa. Endothelial function is measured via a reactive hyperemia (RH) protocol: it consists of a 5 minutes baseline measurement, after which a blood pressure cuff on the test arm is inflated to 60 mm Hg above baseline systolic BP or at least 200 mm Hg for 5 minutes. Occlusion of pulsate arterial flow is confirmed by the reduction of the PAT tracing to zero. After 5 minutes, the cuff is deflated, and the PAT tracing is recorded for a further 5 minutes. The ratio of the PAT signal after cuff release compared with baseline is calculated through a computer algorithm automatically normalizing for baseline signal and indexed to the contra lateral arm. The calculated ratio is called RH-PAT index or RH index (RHI). Its normal value is > 2.00 (pure number), while a clear endothelial dysfunction is shown by a value 1.67 as recommended cutoff value in the user manual of the EndoPAT 2000 device, gathered from clinical data. 17 The EndoPAT test is both operator and interpreter independent.
18,19
| Statistical analysis
Data were presented as mean 6 standard deviation (SD) or Confidential Intervals 95% [CI 95%]. Logarithmic transformation of RHI was used (LnRHI). Subjects were analysed according to different groups (COPD, treated AH patients and Controls) or categories (presence of endothelial dysfunction value RHI 1.67 (LnRHI 0.51) as the median cut-off of distribution, presence of AH). After verifying that data were normally distributed, group comparisons of mean values were performed using t test for independent variables. If data were not normally distributed non-parametrical analysis was performed. Analysis of correlation among variables was performed by multiple regression. Categorical variables were compared by using the chisquare test method. A P value <.05 was considered to be significant. All analyses were performed with the dedicated software (SPSS 21.0 for Windows; SPSS, Chicago, Illinois).
| RES UL TS
| Patients
Demographic and clinical characteristics of subjects studied are reported in Table 1 : groups were matched for age, sex and body mass index (BMI). The control group showed more non-smoking subjects compared to the other groups. No differences among the studied groups were observed for BP data. COPD patients showed impaired FEV 1 and FEV1/ FVC mean data as expected. A summary of the taken medications in the different studied groups was reported in Table  2 . No significant differences in the taken medications were seen between the group of COPD and patients with treated AH.
| Endothelial function
The prevalence of endothelial dysfunction (LnRHI 0.51) was significantly higher in COPD group than in the other groups (75%; 43% and none in COPD, AH and controls, respectively; P < .01). Mean LnRHI was significantly lower in COPD patients compared with the value found in the other groups (0.27 6 0.52; 0.63 6 0.33; 0.85 6 0.13 in COPD, AH and controls, respectively; P < .01) as reported in Figure 1 . It is important to underline that subjects in the group of AH showed intermediate levels of LnRHI significantly different form COPD levels (lower) and control levels (higher). At linear regression FEV 1 and LnRHI were directly correlated ( Figure 2 
| DI S CUS S I ON
The study data showed a higher prevalence of endothelial dysfunction measured with RH-PAT in stable COPD patients compared to controls and treated hypertensive patients. The severity of RHI impairment was higher in stable COPD subjects compared with the other groups and was related to the degree of FEV 1 reduction. AH and COPD seems to be independently related to endothelial dysfunction. Differences in LnRHI observed comparing stable COPD and treated AH patients should not be attributable to different treatments because the two groups were similar with respect to the drug management. Previous studies found a correlation between the presence of endothelial dysfunction and COPD 6, 8, [20] [21] [22] [23] [24] using various techniques and among these only one study using the PAT method. 25 In literature RH-PAT measurements allow to quantify cardiovascular risk 18 and predict late adverse cardiovascular events. 19 The main well known contributing factors for endothelial dysfunction are AH, chronic inflammation, and oxidative stress and metabolic disorders. 26 Bronchial obstruction and bronchial inflammation are strictly related in COPD 27 and bronchial inflammation, is associated with systemic inflammation. 28 Smoking may act through different factors in the development of endothelial dysfunction by altering the balance between oxidants and antioxidants, reducing the production of exhaled nitric oxide and promoting the release of mediators of inflammation and acute phase proteins. All these factors are able to alter the endothelial homeostasis. 29 The correlation between the degree of bronchial obstruction and endothelial dysfunction was constantly observed in previous studies 6, 8, [20] [21] [22] [23] [24] and can be explained by the effects of several factors such as hypoxemia acting through the production of inflammatory cytokines and increasing oxidative stress. 30 In addition, the increase in heart rate and blood pressure and the activation of the reninangiotensin-aldosterone system play a role in the development of endothelial dysfunction induced in COPD with severe disease. 30 
| Study limitations
The small number of subjects in the three groups did not allow a proper analysis of the subpopulations and especially for the influences of the different medications taken. However, the groups appear to be sufficiently homogeneous to obtain a meaningful comparison. Another limiting factor is the presence of many non-smokers subjects in the control group, although according to the analysis of logistic regression smoking is not found to be meaningfully associated with endothelial dysfunction in our study sample. It should be noted that the endothelial dysfunction should be particularly affected by the current smoking habit while in the groups analysed active smokers were equally distributed. The arterial blood gas values and data on oxidative stress or inflammation have not been assessed as this was beyond the objective of the study. Finally a comparison with other detection techniques of endothelial dysfunction such as PWV has not been performed, this could have been an interesting analysis from a methodological standpoint.
| CONC LUS I ON S
Firstly the presence of endothelial dysfunction in patients with stable COPD independently from high blood pressure values is probably implicated in the frequent cardiovascular comorbidity typical of these patients. Secondly the analysis of endothelial dysfunction, with simple technique such as RH-PAT, gave results consistent with those obtained through more complex techniques such as the PWV and the FMD.
The results of the present study suggest the potential utility of endothelial dysfunction evaluation in patients with COPD, in particular the presence of endothelial dysfunction should suggest a more timely evaluation and treatment for CAD. Nevertheless, additional long-term studies are needed to establish the clinical impact of this technique on COPD patients.
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